Robert Berman Biography and Net Worth

Insider of Biohaven

Robert Berman M.D. serves as Lead - Special Projects and Medical Oversight of the Company. Prior to this, from November 2015 to August 2019, he served as chief medical officer. From December 2013 to November 2015, he served as president of Biohaven Medical Services LLC and, prior to that, served as a group director of global clinical research at BMS from September 2003 to November 2013. Prior to his time at BMS, Dr. Berman was an associate director of clinical sciences, early development at Pfizer from November 2000 to September 2003. Since October 2012, Dr. Berman has also continued to serve as an adjunct professor of psychiatry at Yale University School of Medicine. Dr. Berman received his B.A. in molecular biophysics and biochemistry from Yale University and his M.D. from Mount Sinai School of Medicine of New York University.

What is Robert Berman's net worth?: The estimated net worth of Robert Berman is at least $2.68 million as of July 8th, 2020. Dr. Berman owns 58,745 shares of Biohaven stock worth more than $2,678,185 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Berman may own. Learn More about Robert Berman's net worth.
How do I contact Robert Berman?: The corporate mailing address for Dr. Berman and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on Robert Berman's contact information.
Has Robert Berman been buying or selling shares of Biohaven?: Robert Berman has not been actively trading shares of Biohaven within the last three months. Most recently, Robert Berman sold 58,404 shares of the business's stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $75.25, for a transaction totalling $4,394,901.00. Following the completion of the sale, the insider now directly owns 58,745 shares of the company's stock, valued at $4,420,561.25. Learn More on Robert Berman's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

Robert Berman Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/8/2020	Sell	58,404	$75.25	$4,394,901.00	58,745
6/23/2020	Sell	4,296	$75.05	$322,414.80	4,637
6/18/2020	Sell	61,314	$75.27	$4,615,104.78	36,655
12/30/2019	Sell	125,000	$53.22	$6,652,500.00	125,341
6/12/2018	Sell	104,155	$36.33	$3,783,951.15
6/7/2018	Sell	25,845	$36.01	$930,678.45
6/5/2018	Sell	6,362	$36.02	$229,159.24
5/10/2018	Sell	35,000	$26.82	$938,700.00
4/10/2018	Sell	35,000	$24.66	$863,100.00
3/12/2018	Sell	35,000	$30.11	$1,053,850.00
2/12/2018	Sell	35,000	$30.42	$1,064,700.00
1/10/2018	Sell	35,000	$27.52	$963,200.00
12/19/2017	Sell	10,000	$24.10	$241,000.00
12/11/2017	Sell	25,000	$21.28	$532,000.00
11/14/2017	Sell	160,000	$25.76	$4,121,600.00
11/9/2017	Sell	27,423	$26.60	$729,451.80
5/9/2017	Buy	50	$17.00	$850.00

Robert Berman Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $45.59

$44.98

$47.15

50 Day Range

MA: $48.95

$38.08

$53.73

2 Week Range

Now: $45.59

$26.80

$62.21

Volume

691,029 shs

Average Volume

746,157 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.